In a decision that will go a long way in soothing people living with HIV/AIDS (PLHAs), the Indian patent office today turned down the claim of a drug company to patent nevirapine. The drug is critical to HIV/AIDS treatment strategy, and is a crucial part of treatment for children affected by the virus. Patenting the drug would have meant limited access to HIV/AIDS treatment. The decision comes close on the heels of UN General Assembly's high-level meeting on AIDS, where experts admitted to the challenges of achieving universal access to HIV/AIDS care, support and treatment by 2010. The meeting held on June 10 and 11 in New York, highlighted how universal access could not be seen in isolation, and required well-strengthened healthcare delivery system. Such system was presently at skeleton level in most of the developing countries having most of the HIV/AIDS case burden, the meeting concluded. The challenge of treatment is evident in the fact that for every two persons put on anti-retroviral therapy (ART), there are five new infections that are contracted. The UN meet called upon member nations to have trained healthcare manpower to fit in the existing huge gap and play their effective role for universal access target by 2010. "This is a very big task to be achieved within two years,' the experts stated. At present, three million people are put on ART worldwide and by 2010, it is expected that 13 million people will need it. More resource allocation for strengthening of healthcare delivery system by national government is immediately needed to fit into the goal.